Literature DB >> 17305927

Cervical lipomatosis in HIV-infected patients: a case-control study.

R Palacios1, M J Galindo, J A Arranz, F Lozano, V Estrada, A Rivero, D Morales, V Asensi, A del Arco, A Muñoz, J Santos.   

Abstract

OBJECTIVES: The aim of the study was to analyse the prevalence of cervical lipomatosis (CL) in HIV-infected patients on highly active antiretroviral therapy (HAART) and the factors associated with its development.
METHODS: This was a multicentre, observational, 1:1 case-control study. HIV-infected patients with CL (cases) and HIV-infected patients from the same cohort, controlled for age (+/-5 years), sex and body mass index (+/-2.5 kg/m(2)) (controls), were included in the study, and a multiple conditional logistic regression was performed to identify factors related to CL.
RESULTS: CL was reported in 80 patients (1.8%) from a cohort of 4214 patients on HAART followed up in 10 Spanish hospitals. CL was associated with time of exposure to stavudine [for each 6-month increase, odds ratio (OR) 5.82, 95% confidence interval (CI) 5.70-5.94, P=0.0073] and lipoatrophy (OR 8.04, 95% CI 2.93-22.02, P=0.00001).
CONCLUSIONS: Although lipodystrophy is very frequent among HIV-infected patients on HAART, CL is an uncommon type of fat redistribution in this population, and in our cohort it was related to time of exposure to stavudine and lipoatrophy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305927     DOI: 10.1111/j.1468-1293.2007.00421.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  2 in total

1.  Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy.

Authors:  Sher L Hendrickson; Lawrence A Kingsley; Eduardo Ruiz-Pesini; Jason C Poole; Lisa P Jacobson; Frank J Palella; Jay H Bream; Douglas C Wallace; Stephen J O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2009-06-01       Impact factor: 3.731

2.  Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature.

Authors:  Giancarlo Ceccarelli; Gabriella d'Ettorre; Francesco Marchetti; Cecilia Rizza; Claudio M Mastroianni; Bruno Carlesimo; Vincenzo Vullo
Journal:  J Med Case Rep       Date:  2011-02-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.